2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3016 Cytokine signatures of sustained remission off thrombopoietin receptor agonist therapy in pediatric immune thrombocytopenia

Brandon Lucari, MD, Alexander Vargas-Hernandez, PhD2, Jonathan Michael Flanagan, Assistant Professor3, Taylor Kim, MD4, Amanda Grimes, MD5
1 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States, Center for Human Immunobiology, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
3 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
4 Children's Hospital Los Angeles, Los Angeles, California, United States, Keck School of Medicine of USC, Los Angeles, California, United States
5 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States

Introduction

Immune thrombocytopenia (ITP) is the most common autoimmune cytopenia in children. When second-line therapy is required, thrombopoietin receptor agonists (TPO-RAs) are preferentially utilized, and a recent multicenter pediatric trial demonstrated the TPO-RA eltrombopag was superior to standard first-line therapies in producing sustained platelet responses. In adults, more than one-third of patients with ITP being treated successfully with TPO-RAs may be candidates for weaning therapy, yet predictors of sustained remission off treatment (SROT) remain undefined. Biomarkers capable of predicting treatment-free remission could enable individualized TPO-RA weaning. We previously conducted a single-center retrospective study demonstrating that 32.2% of children with persistent or chronic ITP responsive to TPO-RAs achieved SROT at 12 months. Serial plasma samples from this cohort were analyzed to characterize cytokine changes and identify candidate immune signatures associated with durable off-treatment remission.

 

Methods

Plasma samples were obtained from children diagnosed with ITP and enrolled in an IRB-approved biobank within our institution. Viably preserved samples available for analysis were identified retrospectively from a cohort of children receiving at least one TPO-RA (eltrombopag or romiplostim) for persistent or chronic ITP for at least 3 months with documented treatment response, who subsequently weaned TPO-RA therapy and had not received splenectomy or rituximab within 1 year of TPO-RA discontinuation. Serial samples obtained before and during TPO-RA therapy were analyzed from children who achieved SROT (n=5) and those who did not (n=6). SROT was defined as a platelet count ≥30×10⁹/L without bleeding. Multiplex cytokine profiling was performed using bead-based Luminex assays (Eve Technologies). Cytokine concentrations were measured using a 99‑analyte multiplex panel and log transformed prior to analysis. Cytokine changes within patients were compared using paired t‑tests. To evaluate whether cytokine trajectories differed between groups, log‑transformed Δ values were compared using two‑sided Wilcoxon rank‑sum tests. Multiple‑testing correction was performed using the Benjamini–Hochberg false‑discovery rate (FDR). Effect sizes were summarized as group differences in Δ, and raw and FDR‑adjusted p‑values were reported.

 

Results

The SROT group was younger at TPO-RA initiation (median 9.1 vs. 13.2 years), with shorter time from diagnosis to TPO-RA start (median 6.9 vs. 14.2 months). The SROT group took longer to initiate first TPO-RA dose reduction (median 5.3 vs. 1.0 months). At 6 months on TPO-RA therapy, the non-SROT group demonstrated a higher complete response rate (CR: PLT ≥100×10⁹/L without bleeding) than the SROT group (100% vs. 60%).

Analysis of serial plasma pre- and post-TPO-RA therapy revealed distinct cytokine trajectories in both SROT and non-SROT groups. Among SROT patients, FLT‑3L (Δ –0.34, p=0.017, q=0.42), IL‑1β (Δ –0.41, p=0.0068, q=0.36), and lymphotactin (Δ –0.07, p=0.015, q=0.42) decreased post-therapy. In contrast, chemokines associated with neutrophil recruitment and T‑cell trafficking, including GCP‑2 (Δ +0.44, p=0.020, q=0.27), I‑TAC (Δ +0.27, p=0.0097, q=0.25), CXCL16 (Δ +0.12, p=0.045, q=0.37), CTACK (Δ +0.12, p=0.045, q=0.37), TARC (Δ +0.24, p=0.025, q=0.27), TGF‑β1 (Δ +0.39, p=0.021, q=0.27), and APRIL (Δ +0.38, p=0.025, q=0.27) increased post-therapy in non-SROT patients.

A greater reduction in TARC was observed in children achieving SROT than non-SROT (p=0.038, q=0.85).

Conclusion

In this pilot analysis of serial plasma from children weaning TPO‑RA therapy, pro-inflammatory and immune activators decreased in SROT patients; while neutrophil and T‑cell‑trafficking chemokines increased in patients failing to achieve sustained remission off TPO-RA therapy. A significant reduction in TARC, a known T cell regulator, was noted in SROT vs. non-SROT patients when comparing changes between the 2 groups – making TARC a potential candidate biomarker of durable off treatment remission. Although several cytokines demonstrated biologically meaningful paired shifts, no analytes remained significant after FDR correction, underscoring the exploratory nature of this study and the need for validation in larger cohorts. However, the patterns noted align with prior adult studies and support the hypothesis that sustained remission after TPO‑RA withdrawal reflects attenuation of immune activation.

Brandon Lucari, MD: No relevant conflicts of interest to declare.